Newsroom
Sorted by: Latest
-
Rivercell inicia projeto com investimento de US$ 25 milhões para desenvolver plataformas de dados e modelos de IA que preveem como as células humanas respondem ao tratamento
PARIS--(BUSINESS WIRE)--A Rivercell, empresa de biotecnologia e IA com sede em Paris, que vem construindo sua própria infraestrutura de dados sobre como as células humanas respondem a qualquer tratamento e treinando um modelo mundial da célula capaz de prever estas respostas, anunciou hoje uma rodada de investimento inicial de US$ 25 milhões liderada pela HV. A HCVC, a Alven e a Bpifrance Digital Venture também participaram da rodada, que irá financiar a expansão da plataforma proprietária de g...
-
The Law Offices of Frank R. Cruz Announces Investigation of Universe Pharmaceuticals INC. (UPC) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Universe Pharmaceuticals INC. ("Universe Pharmaceuticals" or the "Company") (NASDAQ: UPC) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE A UNIVERSE PHARMACEUTICALS INC. (UPC) SHAREHOLDER, CLICK HERE TO PARTICIPATE.If you still hold Universe Pharmaceuticals INC. shares purchased before May 2026 and wish to discuss this matter wit...
-
Virtus Dividend, Interest & Premium Strategy Fund Announces Final Results of Tender Offer
HARTFORD, Conn.--(BUSINESS WIRE)--Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) (the “Fund”) today announced the final results of its previously announced tender offer (“Tender Offer”) to acquire up to 25% of its outstanding shares. The Tender Offer expired October 5, 2026, at 5:00 p.m. (Eastern). The Fund accepted 23,241,811 shares, representing 25% of its outstanding shares, for payment on or about October 13, 2026. A total of 28,811,699 shares were properly tendered. Ther...
-
Levi Strauss & Co. Reports Third-Quarter Results
SAN FRANCISCO--(BUSINESS WIRE)--Levi Strauss & Co. (NYSE: LEVI) today announced financial results for the third quarter ended August 30, 2026. “Our third-quarter performance highlighted the power of our diversified portfolio and reinforced our confidence that we have the right strategies in place,” said Michelle Gass, President and CEO of Levi Strauss & Co. “We saw strong growth in our international and wholesale businesses, and continued momentum across our lifestyle categories. While...
-
Prime Healthcare Services, Inc. Schedules 2026 3rd Quarter Earnings Conference Call
ONTARIO, Calif.--(BUSINESS WIRE)--Prime Healthcare Services will post earnings on Friday November 13th, to be followed by a conference call on November 16th at 2:00 p.m. (ET) to discuss the reported results.Please ensure you pre-register prior to the call by emailing EGarcia27@primehealthcare.com to facilitate attaining your individual pin that will allow direct access to the call. Access to the call will not be available to those who have not registered in advance.For those who are unable to li...
-
Chiron Real Estate Appoints Charles P. Fitzgerald Chairman of the Board
BETHESDA, Md.--(BUSINESS WIRE)--Chiron Real Estate Inc. (NYSE: XRN) (the “Company” or “Chiron”) announced today that its Board of Directors has appointed Charles P. Fitzgerald as Chairman of the Board, effective immediately. Jeffrey Busch, the Company’s founder and outgoing Chairman, will remain a director following this transition. Mr. Fitzgerald has served as a director of Chiron since May 2026 and is the Founder and Managing Partner of Maewyn Capital Partners LLC (“Maewyn”), a Dallas-based i...
-
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh...
-
Wolfspeed Announces Conditional 30-Year, $1.5 Billion Loan Commitment from U.S. Department of War to Advance Domestic Wide Bandgap Supply Chain
DURHAM, N.C.--(BUSINESS WIRE)--Wolfspeed, Inc. (NYSE: WOLF) today announced it has received a conditional loan commitment letter from the U.S. Department of War (“DoW”), through its Office of Strategic Capital (“OSC”), for up to $1.5 billion of long-term financing to support the domestic development and production of silicon carbide (SiC) materials and wide bandgap power devices, with an additional focus on U.S. national security applications. Beyond supporting the domestic wide bandgap supply...
-
Dominion Energy Schedules Third-Quarter 2026 Earnings Call
RICHMOND, Va.--(BUSINESS WIRE)--Dominion Energy (NYSE: D) will host its third-quarter 2026 earnings call at 11 a.m. ET on Friday, October 30, 2026. Management will discuss matters of interest to financial and other stakeholders including recent financial results. A live webcast of the conference call, including accompanying slides and other financial information, will be available on the investor information pages at investors.dominionenergy.com. For individuals who prefer to join via telephone...
-
Pega to Announce Financial Results for the Third Quarter of 2026 and Host Conference Call and Webcast
WALTHAM, Mass.--(BUSINESS WIRE)--Pegasystems Inc. (NASDAQ: PEGA), the enterprise AI software company for mission-critical work, today announced it will report financial results for the third quarter of 2026 on Tuesday, October 20, 2026, after market close. A conference call and audio-only webcast will be conducted at 8:00 a.m. EDT on Wednesday, October 21, 2026. Members of the public and investors are invited to join the call and participate in the question and answer session by dialing 1 (833)...